Memorial Sloan-Kettering Cancer Center (MSKCC) Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental Biology, Genomic Integrity, and Molecular Structure);Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the ten research programs depends on services provided by 34 core facilities, 19 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs;therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquiry and to support the core facilities which have grown to support the needs of the research enterprise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-47S6
Application #
8733796
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2014-12-31
Budget Start
2012-01-09
Budget End
2014-12-31
Support Year
47
Fiscal Year
2013
Total Cost
$238,405
Indirect Cost
$97,002
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Kim, Jisun; Geyer, Felipe C; Martelotto, Luciano G et al. (2018) MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. J Pathol 244:143-150
Neuschmelting, Volker; Kim, Kwanghee; Malekzadeh-Najafabadi, Jaber et al. (2018) WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice. Theranostics 8:723-734
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Turesson, Ingemar; Bjorkholm, Magnus; Blimark, Cecilie Hveding et al. (2018) Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol :
Moo, Tracy-Ann; Edelweiss, Marcia; Hajiyeva, Sabina et al. (2018) Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Ann Surg Oncol 25:1488-1494
Kinsley, Karen; Pritchett, Wendy (2018) Liposomal Irinotecan: Nursing Considerations in an Outpatient Cancer Center Clin J Oncol Nurs 22:221-224
Vargas, Hebert Alberto; Kramer, Gem M; Scott, Andrew M et al. (2018) Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med 59:1516-1523
Ho, A L (2018) Developing androgen receptor targeting for salivary gland cancers. Ann Oncol 29:792-794
Gupta, Piyush; Migliacci, Jocelyn C; Hay, Ashley et al. (2018) Validation and assessment of discordance of the 8th edition AJCC (American Joint Committee on Cancer) clinical and pathologic staging systems in patients with p16+ oropharyngeal cancer treated with surgery and adjuvant radiation at a single institution. Oral Oncol 83:140-146
Aras, Omer; Pearce, Gillian; Watkins, Adam J et al. (2018) An in-vivo pilot study into the effects of FDG-mNP in cancer in mice. PLoS One 13:e0202482

Showing the most recent 10 out of 8799 publications